In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL

References

• Ballestrero A, Montemurro F, Gonella R, Capaldi A, Danova M, Friedman D, Puglisi M, Aglietta M, Patrone F 2003. Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti- tumor activity and peripheral blood progenitor cell mobilization capability. Breast Cancer Res Treat. 82, 185–190.
   Google Scholar
• Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC 2004. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11, 915–923.
   PubMed Web of Science ®Google Scholar
• Elbayoumi TA, Pabba S, Roby A, Torchilin VP 2007. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 17, 1–14.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590–1598.
   PubMed Web of Science ®Google Scholar
• Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O’Bryan E, Fumero C, Wang HG, Bhalla K 2002. Ectopic overexpression of second mitochondria- derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99, 3419–3426.
   PubMed Web of Science ®Google Scholar
• Iakoubov LZ, Torchilin VP 1997. A novel class of antitumor antibodies: Nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res. 9, 439–446.
   PubMed Web of Science ®Google Scholar
• Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC 2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6, 564–567.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y 2006. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur. J. Pharm. Sci. 28, 7–14.
   PubMed Web of Science ®Google Scholar
• Kelley SK, Ashkenazi A 2004. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333–339.
   PubMed Web of Science ®Google Scholar
• Kwon GS, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K 1995. Physical entrapment of adriamycin in AB block copolymer micelles. Pharm. Res. 12, 192–195.
   PubMed Web of Science ®Google Scholar
• Lee H, Hu M, Reilly RM, Allen C 2007. Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Mol. Pharm. 4, 769–781.
   PubMed Web of Science ®Google Scholar
• Lukyanov AN, Gao Z, Mazzola L, Torchilin V 2002. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm. Res. 19, 1424–9.
   PubMed Web of Science ®Google Scholar
• Maeda H 2001. The enhanced permeability retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189–207.
   PubMedGoogle Scholar
• Mallick S, Pattnaik S, Swain K, De PK 2007. Current perspectives of solubilization: potential for improved bioavailability. Drug Dev. Ind. Pharm. 33, 865–873.
   PubMed Web of Science ®Google Scholar
• Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP 1985. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog Agents Actions 16, 470–477.
   PubMedGoogle Scholar
• Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM 1997a. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815–818.
   PubMed Web of Science ®Google Scholar
• Pan G, O’Rourke K, Chinnaiyan A, Gentz R, Ebner R, Ni J, Dixit VM 1997b. The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113.
   PubMed Web of Science ®Google Scholar
• Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C, Liu X 2004. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39, 1371–1381.
   PubMed Web of Science ®Google Scholar
• Rajebahadur M, Zia H, Nues A, Lee C 2006. Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or solutol HS-15. Drug Deliv. 13, 201–206.
   PubMed Web of Science ®Google Scholar
• Roby A, Erdogan S, Torchilin V 2006. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur. J. Pharm. Biopharm. 62, 235–240.
   PubMed Web of Science ®Google Scholar
• Safavy A, Raisch K, Mantena S, Sanford L, Sham S, Krishna N, Bonner J 2007. Design and development of water-soluble curcumin conjugates as potential anticancer agents. 50, 6284–6288.
   Google Scholar
• Scripture C, Figg WD, Sparreboom A 2005. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther. Clin. Risk Manag. 1, 107–114.
   PubMedGoogle Scholar
• Sethuraman V, Bae YH 2007. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Contr. Rel. 118, 216–224.
   PubMed Web of Science ®Google Scholar
• Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821.
   PubMed Web of Science ®Google Scholar
• Skidan I, Degterev A, Torchilin V 2007. Micellar form of novel poorly soluble proapoptotic agent, Dimethyl-PIT. 2007. 34th Annual CRS meeting, Long Beach, CA, July 7–11, 2007, Abstract #247.
   Google Scholar
• Skidan I, Dholakia P, Torchilin V 2008a. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. J. Drug Target. 16, 486–493.
   PubMed Web of Science ®Google Scholar
• Skidan I, Dholakia P, Degterev A, Torchilin V 2008b. PEG-PE micelles with novel poorly-soluble proapoptotic agent: activity in vivo. 35th Annual CRS meeting, New York, July 12–16, Abstract #648.
   Google Scholar
• Torchilin V 2007. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1–16.
   PubMed Web of Science ®Google Scholar
• Torchilin V, Levchenko T, Lukyanov A, Khaw B, Klibanov A, Rammohan R, Samokhin G, Whiteman K 2001. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511, 397–411.
   PubMed Web of Science ®Google Scholar
• Torchilin V, Lukyanov A, Gao Z, Papahadjopoulos-Sternberg B 2003. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. USA 100, 6039–6044.
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A 2001. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother. Pharmacol. 47, 309–318.
   PubMed Web of Science ®Google Scholar
• Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S 2008. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 348, 137–145.
   PubMed Web of Science ®Google Scholar